5'-硝基-螺[咪唑烷-4,2'-茚满]-2,5-二酮 | 33584-66-6

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 中文名称: 5'-硝基-螺[咪唑烷-4,2'-茚满]-2,5-二酮
• 英文名称: (+/-)-5'-nitro-1',3'-dihydro-2H,5H-spiro[imidazolidine-4,2'-indene]-2,5-dione
• 英文别名: 5'-nitro-1',3'-dihydrospiro[imidazolidine-4,2'-indene]-2,5-dione；(+/-)-5'-nitro-spiro[imidazolidine-4,2'-indane]-2,5-dione；(+/-)-5'-nitrospiro[imidazolidine-4,2'-indane]-2,5-dione；5'-nitro-spiro[imidazolidine-4,2'-indane]-2,5-dione；Spiro(5-nitroindane)-2,5'-hydantoin；5-nitrospiro[1,3-dihydroindene-2,5'-imidazolidine]-2',4'-dione
• CAS: 33584-66-6
• 化学式: C₁₁H₉N₃O₄
• 分子量: 247.21
• InChiKey: MTLBOQSPYBYFJF-UHFFFAOYSA-N

物化性质

• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  18
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5'-硝基-螺[咪唑烷-4,2'-茚满]-2,5-二酮 在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-(2',5'-dioxospiro[1,3-dihydroindene-2,4'-imidazolidine]-5-yl)-2-(2-oxo-3H-benzimidazol-1-yl)acetamide
  参考文献：
  名称：

  Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists

  摘要：

  A rapid analogue approach to identification of spirohydantoin-based CGRP antagonists provided novel, low molecular weight leads. Modification of these leads afforded a series of nanomolar benzimidazolinone-based CGRP receptor antagonists. The oral bioavailability of these antagonists was inversely correlated with polar surface area, suggesting that membrane permeability was a key limitation to absorption. Optimization provided compound 12, a potent CGRP receptor antagonist (K-i = 21 nM) with good oral bioavailability in three species. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.045
• 作为产物：
  描述：

  1',3'-二氢螺[咪唑烷-4,2'-茚]-2,5-二酮 在 硝酸 作用下， 反应 1.0h， 生成 5'-硝基-螺[咪唑烷-4,2'-茚满]-2,5-二酮
  参考文献：
  名称：

  [EN] CGRP RECEPTOR ANTAGONISTS
  [FR] ANTAGONISTES DE RÉCEPTEURS DE CGRP

  摘要：

  公式（I）的化合物（其中变量A1、A2、A3、环B、m、n、J、E1、E2、E3、R5、RPG和Y如本文所述），这些化合物可用作CGRP受体的拮抗剂，并可用于治疗或预防涉及CGRP受体的疾病，如头痛，特别是偏头痛和群集性头痛。该发明还涉及包含公式（I）化合物的制药组合物以及在涉及CGRP受体的疾病的预防或治疗中使用这些化合物和组合物的用途。

  公开号：

  WO2010107605A1

文献信息

• [EN] ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR CGRP D'ARYL SPIROHYDANTOINE
  申请人：MERCK & CO INC

  公开号：WO2004082678A1

  公开（公告）日：2004-09-30

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及一种对CGRP受体具有拮抗作用的化合物，可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和集群头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗CGRP参与的这类疾病中使用这些化合物和组合物。
• [EN] MONOCYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS DU CGRP D'ANILIDE SPIROHYDANTOINE MONOCYCLIQUE
  申请人：MERCK & CO INC

  公开号：WO2004083187A1

  公开（公告）日：2004-09-30

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及一类CGRP受体拮抗剂化合物，用于治疗或预防涉及CGRP的疾病，如头痛、偏头痛和群集性头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的疾病中使用这些化合物和组合物。
• [EN] BICYCLIC DIHYDROIMIDAZOLONE CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DU CGRP À BASE DE DIHYDROIMIDAZOLONE BICYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010033421A1

  公开（公告）日：2010-03-25

  Compounds of formula (I): wherein variables B, G1, G2, G3, G4, Ea, Eb, Ec, A1, A2, A3, A4, R6 and RPG and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式（I）化合物：其中变量B、G1、G2、G3、G4、Ea、Eb、Ec、A1、A2、A3、A4、R6和RPG以及Y如本文所述，它们是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗CGRP参与的疾病中的用途。
• Monocyclic anilide spirohydantoin cgrp receptor antagonists
  申请人：Bell M. Ian

  公开号：US20060148779A1

  公开（公告）日：2006-07-06

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及与CGRP受体拮抗的化合物，这些化合物在治疗或预防CGRP参与的疾病，如头痛、偏头痛和群头痛方面是有用的。本发明还涉及包含这些化合物的药物组合物，以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
• Aryl spirohydantoin cgrp receptor antagonists
  申请人：Bell M. Ian

  公开号：US20060189593A1

  公开（公告）日：2006-08-24

  The present invention is directed to compounds that are antagonists of CGRP receptors and that are useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及对CGRP受体的拮抗剂化合物，这些化合物可用于治疗或预防CGRP参与的疾病，如头痛、偏头痛和群集性头痛。本发明还涉及包含这些化合物的制药组合物和使用这些化合物和组合物预防或治疗CGRP参与的这些疾病。